183 282

Cited 0 times in

유전자 1형 만성 C형간염 환자에서 페그인터페론과 리바비린의 24주와 48주 치료 효과 비교

Other Titles
 A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis 
 김미나  ;  윤기태  ;  박준용  ;  김도영  ;  안상훈  ;  전재윤  ;  한광협 
 Korean Journal of Hepatology (대한간학회지), Vol.15(4) : 496-503, 2009 
Journal Title
 Korean Journal of Hepatology (대한간학회지) 
Issue Date
Adult ; Age Factors ; Aged ; Antiviral Agents/administration & dosage* ; Antiviral Agents/therapeutic use ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/genetics ; Hepatitis C, Chronic/drug therapy* ; Humans ; Interferon-alpha/administration & dosage* ; Interferon-alpha/therapeutic use ; Male ; Middle Aged ; Multivariate Analysis ; Polyethylene Glycols/administration & dosage* ; Polyethylene Glycols/therapeutic use ; RNA, Viral/blood ; Recombinant Proteins ; Ribavirin/administration & dosage* ; Ribavirin/therapeutic use
Chronic hepatitis C ; Genotype 1 ; Peginterferon ; Ribavirin
Background/Aims: The standard therapy for patients with genotype 1 chronic hepatitis C (CHC) is a combination of peginterferon and ribavirin for 48 weeks. However, the most appropriate duration of treatment remains to be established because of treatment-related side effects and cost. The aim of this study was to compare the efficacies of 24- and 48-week treatments, and to assess the efficacy of split 24-week therapy (a further 24 weeks of treatment in patients with relapse after the initial 24 weeks of treatment). Methods: A total of 130 patients with genotype 1 CHC was treated between June 2004 and December 2006. Patients with undetectable HCV RNA at 24 weeks of treatment (as assessed by qualitative PCR assay; n=101 patients) were allowed to choose either 24 or 48 weeks as the duration of their treatment; 51 patients chose the 24-week treatment regimen and the remainder chose the 48-week regimen. Patients who relapsed after 24 weeks of treatment were treated for further 24 weeks. The sustained virologic response (SVR) of each treatment group was analyzed. Results: The SVR rate was higher in patients treated for 48 weeks than in those treated for 24 weeks (74.0% vs. 52.9%, P=0.028). In the multivariate analysis, age < 50 years, platelets ≥ 150,000/mm3, and treatment duration for 48 weeks remained significant independent predictors of SVR. Fourteen of the 24 patients who relapsed in the 24-week treatment group received split 24-week therapy, and 6 patients (42.9%) achieved SVR. The overall SVR rate did not differ significantly between the 24-week treatment group, including those who underwent 24-week split therapy (64.7%), and the 48-week treatment group (64.7% vs. 74%, P=0.311). Conclusions: The 24-week plus additional split 24-week therapy following failure is a useful treatment strategy for patients with genotype 1 CHC
Files in This Item:
T200905806.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Kim, Mi Na(김미나)
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Chon, Chae Yoon(전재윤)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.